Exagen Inc (NASDAQ:XGN) — Market Cap & Net Worth
Market Cap & Net Worth: Exagen Inc (XGN)
Exagen Inc (NASDAQ:XGN) has a market capitalization of $69.35 Million ($69.35 Million) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #20599 globally and #4432 in its home market, demonstrating a 14.18% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Exagen Inc's stock price $3.06 by its total outstanding shares 22663099 (22.66 Million). Analyse Exagen Inc (XGN) cash conversion ratio to see how efficiently the company converts income to cash.
Exagen Inc Market Cap History: 2019 to 2026
Exagen Inc's market capitalization history from 2019 to 2026. Data shows change from $575.64 Million to $69.35 Million (-22.90% CAGR).
Index Memberships
Exagen Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #590 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1994 of 3165 |
Weight: Exagen Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Exagen Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Exagen Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.67x
Exagen Inc's market cap is 1.67 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $575.64 Million | $40.39 Million | -$12.04 Million | 14.25x | N/A |
| 2020 | $299.15 Million | $41.98 Million | -$16.69 Million | 7.13x | N/A |
| 2021 | $263.57 Million | $48.30 Million | -$26.85 Million | 5.46x | N/A |
| 2022 | $54.39 Million | $45.56 Million | -$47.39 Million | 1.19x | N/A |
| 2023 | $45.10 Million | $52.55 Million | -$23.69 Million | 0.86x | N/A |
| 2024 | $92.92 Million | $55.64 Million | -$15.12 Million | 1.67x | N/A |
Competitor Companies of XGN by Market Capitalization
Companies near Exagen Inc in the global market cap rankings as of May 2, 2026.
Key companies related to Exagen Inc by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #126 globally with a market cap of $176.29 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #189 globally with a market cap of $123.72 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #578 globally with a market cap of $45.31 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #643 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #126 | Thermo Fisher Scientific Inc | NYSE:TMO | $176.29 Billion | $469.21 |
| #189 | Danaher Corporation | NYSE:DHR | $123.72 Billion | $175.15 |
| #578 | IDEXX Laboratories Inc | NASDAQ:IDXX | $45.31 Billion | $567.46 |
| #643 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
Exagen Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, Exagen Inc's market cap moved from $575.64 Million to $ 69.35 Million, with a yearly change of -22.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $69.35 Million | -49.67% |
| 2025 | $137.79 Million | +48.29% |
| 2024 | $92.92 Million | +106.03% |
| 2023 | $45.10 Million | -17.08% |
| 2022 | $54.39 Million | -79.36% |
| 2021 | $263.57 Million | -11.89% |
| 2020 | $299.15 Million | -48.03% |
| 2019 | $575.64 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Exagen Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $69.35 Million USD |
| MoneyControl | $69.35 Million USD |
| MarketWatch | $69.35 Million USD |
| marketcap.company | $69.35 Million USD |
| Reuters | $69.35 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Exagen Inc
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing produc… Read more